Immunome/$IMNM

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Ticker

$IMNM
Primary listing

Industry

Biotechnology

Employees

131

ISIN

US45257U1088

Immunome Metrics

BasicAdvanced
$765M
-
-$3.13
2.01
-

What the Analysts think about Immunome

Analyst ratings (Buy, Hold, Sell) for Immunome stock.

Bulls say / Bears say

Immunome's CEO, Clay B. Siegall, demonstrated confidence in the company's future by purchasing 137,100 shares on March 26, 2025, at an average price of $7.29 per share, totaling approximately $999,459.00. (marketbeat.com)
Analysts have expressed optimism about Immunome's prospects, with Wedbush maintaining an 'outperform' rating and setting a price target of $33.00 as of March 20, 2025. (etfdailynews.com)
The successful completion of a $150 million public offering in January 2025 has bolstered Immunome's financial position, providing capital to advance its pipeline of targeted cancer therapies. (nasdaq.com)
Following the announcement of the $150 million public offering priced at $7.75 per share, Immunome's stock experienced a 9.6% decline, indicating potential investor concerns about dilution. (investing.com)
Immunome has reported significant operating losses, with an accumulated deficit of approximately $181.7 million as of December 31, 2024, raising concerns about its path to profitability. (dcfmodeling.com)
The biotechnology sector is highly competitive, and Immunome faces challenges from larger pharmaceutical companies, which could impact its market share and revenue growth. (dcfmodeling.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

Immunome Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunome Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMNM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs